-5%
Otezol is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential. If specimens for fungal culture are obtained prior to therapy, antifungal therapy may be instituted before the results of the cultures are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Oteseconazole is an antifungal agent whose precise exposure-response relationship and timeline of pharmacologic action have not been fully established. It functions by inhibiting CYP51 (14α-demethylase), a key enzyme involved in the early stages of ergosterol synthesis, which is vital for the development and stability of fungal cell membranes. By blocking this enzyme, oteseconazole leads to the build-up of 14-methylated sterols, compounds that are harmful to fungal cells. Its tetrazole-based structure allows it to bind metal ions, enhancing its selectivity for fungal enzymes and minimizing interaction with human CYP enzymes.